Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT04498117IIINewly diagnosed BRCA WT and HRD- stage III/IV ovarian cancer following optimal cytoreduction at primary or interval surgeryA Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaAZ, CA, CO, CT, FL, GA, HI, IL, IN, LA, MA, MI, MN, NE, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
OregovomabOvaRex, Monoclonal Antibody B43.13, B43.13Immune response against cancer expressing CA125Clinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03772028IIINewly diagnosed stage III ovarian cancer eligible for primary cytoreductive surgeryPhase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal ChemotherapyNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
NCT04095364IIINewly diagnosed stage II-IV low grade serous ovarian cancer that is TP53 WTA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumAK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04606914IINewly diagnosed stage III-IV high grade serous FRalpha+ ovarian cancer (neoadjuvant)Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α PositiveALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT02834975IINewly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant ChemotherapyFLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04082572IINewly diagnosed advanced solid tumors with dMMR or high MSINeoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid CancersTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03393884I/IINewly diagnosed stage III/IV ovarian cancer (neo-adjuvant) (Phase II)A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerAL, CA, FL, MA, MO, NJ, NY, OK, OR, SD, TN, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GEN-1PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPCIL-12 receptor agonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04024878INewly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence) (neo-adjuvant or adjuvant and maintenance)NeoVax With Nivolumab in Patients With Ovarian CancerMAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NeoVaxImmune response against neoantigensClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04847063IOvarian cancer with peritoneal disease - expected to undergo complete cytoreductionIndividualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
FloxuridineWR-138720, 5-FUDRRNA and DNA synthesis inhibitor
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
Mitomycin CAmetycine, MITO-C, Mitocin, Mitolem, Mitosol, Mitozytrex, Mutamycin, NCI-C04706DNA synthesis inhibitorApproved in Other Cancers
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
SurgeryClinical Trials
NCT03839524IHigh grade serous ovarian cancer with complete response after surgery and first-line platinum therapy (w/ banked tumor tissue)A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.AZ, FL, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TG4050Modified Vaccinia Ankara (MVA) personalized vaccine, MyVACImmune response against neoantigensClinical Trials
NCT05145569INewly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant)A Phase 1b, Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bintrafusp alfaMSB0011359C, M7824TGFbeta trap and blocks PD-L1 inhibition of T cellsClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02659241INewly diagnosed high grade serous ovarian cancer (neo-adjuvant)A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian CancerOR, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitorClinical Trials
NCT04598321INewly diagnosed stage II-IV, BRCA MUT, mixed epithelial carcinoma, high grade serous or endometrioid ovarian cancer (neo-adjuvant)BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)RIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT03943173INewly diagnosed BRCA MUT ovarian cancer (neo-adjuvant)NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian CancerTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.